Tandem Diabetes Care (TNDM) Long-Term Investments (2014 - 2026)

Tandem Diabetes Care has reported Long-Term Investments for 6 years, with the latest figure at $56.5 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Investments fell 20.44% year-over-year to $56.5 million; the trailing twelve-month figure through Mar 2026 stood at $56.5 million (down 20.44% YoY), and the FY2025 full-year result was $60.4 million, down 18.93% from the prior year.
• Long-Term Investments for Q1 2026 stood at $56.5 million, down from $60.4 million in the prior quarter.
• The five-year high for Long-Term Investments was $74.5 million in Q4 2024, with the low at $56.5 million in Q1 2026.
• Historically, Long-Term Investments has averaged $65.8 million across 3 years, with a median of $66.3 million in 2025.
• Annual changes were most pronounced in 2025 — Long-Term Investments fell 18.93% — and 2026, when it decreased 20.44%.
• Tandem Diabetes Care's Long-Term Investments stood at $74.5 million in 2024, then fell by 18.93% to $60.4 million in 2025, then retreated by 6.48% to $56.5 million in 2026.
• The last three Long-Term Investments figures came in at $56.5 million (Q1 2026), $60.4 million (Q4 2025), and $64.9 million (Q3 2025), per Business Quant data.